Form 4: Lixte Biotechnology Director Receives Stock Options in Lieu of Cash Compensation

Regina Brown, a director at Lixte Biotechnology Holdings, Inc., received 4,924 stock options in lieu of cash compensation.

Summary

• Regina Brown, a director of Lixte Biotechnology Holdings, Inc., was granted 4,924 stock options on January 20, 2025.
• These options were granted in lieu of her quarterly cash compensation under the Board Compensation Plan.
• The options have an exercise price of $2.33 and vest immediately.
• The options expire on January 20, 2030.
• Ms. Brown also holds other options with various exercise prices and expiration dates.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice, which is generally neutral to positive. The use of stock options can be seen as a positive sign of aligning director interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The immediate vesting of the options provides an immediate incentive for the director.
• The use of stock options in lieu of cash compensation may help the company conserve cash.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• The director may not exercise the options if the stock price does not reach the exercise price.

Management Comments

• The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Industry Context

The use of stock options as part of director compensation is a common practice in the biotechnology industry to align the interests of management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of immediately vested options is not uncommon, especially for smaller grants.
• The exercise prices of the options are generally set at or above the market price at the time of grant, which is typical.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of aligning director interests with company performance.
• The use of stock options in lieu of cash compensation may be seen as a positive for the company's cash position.

Key Dates

Keywords

stock options, director compensation, Lixte Biotechnology, insider trading, equity, Regina Brown